Back

Cannabidiol (CBD) repurposing as antibacterial: promising therapy of CBD plus polymyxin B against superbugs

Abichabki, N.; Zacharias, L. V.; Moreira, N. C.; Bellissimo-Rodrigues, F.; Moreira, F. d. L.; Benzi, J. R. d. L.; Ogasawara, T. M. C.; Ferreira, J. C.; Pereira, L. R. L.; Braga, G. U. L.; Ribeiro, C. M.; Pavan, F. R.; Zuardi, A. W.; Hallak, J. E. C.; Crippa, J. A. d. S.; Lanchote, V. L.; Canton, R.; Darini, A. L. C.; Andrade, L. N.

2021-04-12 microbiology
10.1101/2021.04.12.439341 bioRxiv
Show abstract

Abstract Multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria are a major worldwide public health problem. In the last decades, resistance to last-resort antibiotics such as polymyxin B (PB) have been increasingly observed among these superbugs, compromising the effectiveness of antimicrobial therapy. The present study aimed (i) to assess the ultrapure Cannabidiol (CBD) antibacterial activity against a broad diversity of Gram-negative (GN) and Gram-positive (GP) bacteria (44 different species, 95 strains), comprising standard strains and clinical isolates, and (ii) to investigate the antibacterial activity of the combination CBD + PB against GN bacteria, including chromosomal- and plasmid-acquired PB-resistant and intrinsically PB-resistant GNB. We evaluated CBD in vitro antibacterial activity using the standard broth microdilution method, and the antibacterial activity of the combination CBD + PB was screened using the standard broth microdilution and confirmed by checkerboard assay. CBD exhibited antibacterial activity against different GP bacterial species, lipooligosaccharide (LOS)-expressing GN diplococcus (GND) (Neisseria gonorrhoeae, Neisseria meningitidis, and Moraxella catarrhalis), and Mycobacterium tuberculosis. The combination CBD + PB exhibited antibacterial activity against PB-resistant GNB (e.g., Klebsiella pneumoniae) as well as additive and/or synergistic effect against LOS-expressing GND. The antibacterial activity of the combination CBD + PB against Pseudomonas aeruginosa and plasmid-mediated colistin-resistant (MCR-1) E. coli strains could be only demonstrated in the presence of phenylalanine-arginine-{beta}-naphthylamide (PA{beta}N). In conclusion, our results show promising translational potential of the combination CBD + PB against MDR and XDR GNB, including PB-resistant K. pneumoniae, highlighting its potential as a rescue treatment for life-threatening infections caused by these superbugs. One Sentence SummaryPromising combination of cannabidiol (CBD) + polymyxin B (PB) against superbugs (e.g., PB-resistant Gram-negative bacilli): Repurposing CBD

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 0.1%
37.7%
2
International Journal of Antimicrobial Agents
15 papers in training set
Top 0.1%
12.3%
3
Microbiology Spectrum
435 papers in training set
Top 0.1%
8.2%
50% of probability mass above
4
Antibiotics
32 papers in training set
Top 0.2%
6.8%
5
Scientific Reports
3102 papers in training set
Top 41%
3.1%
6
Journal of Global Antimicrobial Resistance
15 papers in training set
Top 0.2%
2.9%
7
ACS Infectious Diseases
74 papers in training set
Top 0.4%
2.6%
8
PLOS ONE
4510 papers in training set
Top 48%
2.1%
9
Frontiers in Medicine
113 papers in training set
Top 4%
1.7%
10
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.7%
11
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 4%
0.9%
12
eLife
5422 papers in training set
Top 53%
0.9%
13
BMC Microbiology
35 papers in training set
Top 1%
0.8%
14
The Lancet Infectious Diseases
71 papers in training set
Top 3%
0.8%
15
PLOS Neglected Tropical Diseases
378 papers in training set
Top 5%
0.7%
16
The Journal of Infectious Diseases
182 papers in training set
Top 5%
0.7%
17
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.7%
18
Pharmaceuticals
33 papers in training set
Top 2%
0.7%
19
Journal of Clinical Microbiology
120 papers in training set
Top 2%
0.7%
20
Journal of Antimicrobial Chemotherapy
43 papers in training set
Top 0.5%
0.7%
21
Journal of Medicinal Chemistry
68 papers in training set
Top 1%
0.6%